References
- Future reviews [Internet]. ALS UntangledTM. [cited 2022 Feb 8]. Available from: https://www.alsuntangled.com/future-reviews/
- Streeten DH. Corticosteroid therapy. II. Complications and therapeutic indications. JAMA 1975;232:1046–9.
- Ericson-Neilsen W, Kaye AD. Steroids: pharmacology, complications, and practice delivery issues. Ochsner J. 2014;14:203–7.
- Murray TJ. Diagnosis and treatment of multiple sclerosis. BMJ. 2006;332:525–7.
- Drake LA, Dinehart SM, Farmer ER, Goltz RW, Graham GF, Hordinsky MK, et al. Guidelines of care for dermatomyositis. American Academy of Dermatology. J Am Acad Dermatol. 1996;34:824–9.
- Sanders DB, Wolfe GI, Benatar M, Evoli A, Gilhus NE, Illa I, et al. International consensus guidance for management of myasthenia gravis: executive summary. Neurology 2016;87:419–25.
- Van den Bergh PYK, Hadden RDM, Bouche P, Cornblath DR, Hahn A, Illa I, et al. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society – first revision. Eur J Neurol. 2010;17:356–63.
- Aiken updates on battle with ALS [Internet]. PublishersWeekly.com. [cited 2022 Feb 8]. Available from: https://www.publishersweekly.com/pw/by-topic/industry-news/people/article/65127-aiken-updates-on-battle-with-als.html
- Executive director of US authors guild has ALS. Aiken says early-stage symptoms in remission with steroids; will make medical records public [Internet]. The Authors Guild. 2013 [cited 2022 Feb 8]. Available from: https://www.authorsguild.org/industry-advocacy/executive-director-of-us-authors-guild-has-als-says-early-stage-symptoms-are-in-remission-with-steroid-treatments-will-begin-making-medical-records-public-on-monday-september-23/
- My ALS remission story [Internet]. [cited 2022 Jan 23]. Available from: http://myalsremissionstory.blogspot.com/
- McCauley ME, Baloh RH. Inflammation in ALS/FTD pathogenesis. Acta Neuropathol. 2019;137:715–30.
- Prinz M, Priller J. The role of peripheral immune cells in the CNS in steady state and disease. Nat Neurosci. 2017;20:136–44.
- AM P, DH R. The role of immune and inflammatory mechanisms in ALS. Curr Mol Med 2011;11:246–54.
- Hooten KG, Beers DR, Zhao W, Appel SH. Protective and toxic neuroinflammation in amyotrophic lateral sclerosis. Neurotherapeutics. 2015;12:364–75.
- Beers DR, Henkel JS, Zhao W, Wang J, Huang A, Wen S, et al. Endogenous regulatory T lymphocytes ameliorate amyotrophic lateral sclerosis in mice and correlate with disease progression in patients with amyotrophic lateral sclerosis. Brain. 2011;134:1293–314.
- Zhao W, Beers DR, Liao B, Henkel JS, Appel SH. Regulatory T lymphocytes from ALS mice suppress microglia and effector T lymphocytes through different cytokine-mediated mechanisms. Neurobiol Dis. 2012;48:418–28.
- Rentzos M, Evangelopoulos E, Sereti E, Zouvelou V, Marmara S, Alexakis T, et al. Alterations of T cell subsets in ALS: a systemic immune activation? Acta Neurol Scand. 2012;125:260–4.
- M.D JDG. A novel immunosuppression intervention for the treatment of amyotrophic lateral sclerosis (ALS) [Internet]. Report No.: NCT01884571. clinicaltrials.gov; 2017. [cited 2021 Jul 26]. Available from: https://clinicaltrials.gov/ct2/show/NCT01884571
- Abbas AK, Trotta E, Simeonov D R, Marson A, Bluestone JA. Revisiting IL-2: biology and therapeutic prospects. Sci Immunol. 2018;3:eaat1482.
- Evans MC, Gaillard PJ, de Boer M, Appeldoorn C, Dorland R, Sibson NR, et al. CNS-targeted glucocorticoid reduces pathology in mouse model of amyotrophic lateral sclerosis. Acta Neuropathol Commun. 2014;2:66.
- Fidler JA, Treleaven CM, Frakes A, Tamsett TJ, McCrate M, Cheng SH, et al. Disease progression in a mouse model of amyotrophic lateral sclerosis: the influence of chronic stress and corticosterone. FASEB J. 2011;25:4369–77.
- Jacobson SA. Two cases of amyotrophic lateral sclerosis treated with cortisone. Neurology 1952;2:166.
- Kamen GF. Intrathecal hydrocortisone and amyotrophic lateral sclerosis; case report; two and one-half years follow up. Med Times. 1957;85:283–9.
- Pieper SJL, Fields WS. Failure of amyotrophic lateral sclerosis to respond to intrathecal steroid and vitamin B12 therapy. Neurology 1959;9:522–522.
- Baumann J. Results of treatment of certain diseases of the central nervous system with ACTH and corticosteroids. Acta Neurol Scand. 2009;41:453–62.
- Tuk B, Jousma H, Gaillard PJ. Treatment with penicillin G and hydrocortisone reduces ALS-associated symptoms: a case series of three patients. F1000Res. 2017;6:410.
- Bedlack R. ALSUntangled 46: penicillin G/hydrocortisone. Amyotroph Lateral Scler Frontotemporal Degener. 2019;20:126–31. Feb
- PatientsLikeMe [Internet]. PatientsLikeMe. [cited 2022 Mar 2]. Available from: https://www.patientslikeme.com/treatment_evaluations/browse?id=prednisone
- Dexamethasone [Internet]. PatientsLikeMe. [cited 2022 Mar 2]. Available from: https://www.patientslikeme.com/treatment/dexamethasone
- PatientsLikeMe [Internet]. PatientsLikeMe. [cited 2022 Mar 2]. Available from: https://www.patientslikeme.com/treatment_evaluations/browse?id=dexamethasone
- Hydrocortisone: uses & side-effects | PatientsLikeMe [Internet]. [cited 2022 Mar 2]. Available from: https://www.patientslikeme.com/treatment/hydrocortisone
- Van Es MA, Van Eijk RPA, Bunte TM, Van Den Berg LH. A placebo-controlled trial to investigate the safety and efficacy of Penicillin G/Hydrocortisone in patients with ALS (PHALS trial). Amyotroph Lateral Scler Frontotemporal Degener. 2020;21:584–92.
- Fournier CN, Schoenfeld D, Berry JD, Cudkowicz ME, Chan J, Quinn C, et al. An open label study of a novel immunosuppression intervention for the treatment of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2018;19:242–9.
- Werdelin L, Boysen G, Jensen TS, Mogensen P. Immunosuppressive treatment of patients with amyotrophic lateral sclerosis. Acta Neurol Scand. 1990;82:132–4.
- Tan E, Lynn DJ, Amato AA, Kissel JT, Rammohan KW, Sahenk Z, et al. Immunosuppressive treatment of motor neuron syndromes: attempts to distinguish a treatable disorder. Arch Neurol. 1994;51:194–200.
- Yeh WZ, Dyck PJ, van den Berg L., Kiernan MC, Taylor BV. Multifocal motor neuropathy: controversies and priorities. J Neurol Neurosurg Psychiatry. 2020;91:140–8.
- Liu D, Ahmet A, Ward L, Krishnamoorthy P, Mandelcorn ED, Leigh R, et al. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy Asthma Clin Immunol off J Can Soc Allergy Clin Immunol 2013;9:30.
- Pereira RMR, Freire de Carvalho J. Glucocorticoid-induced myopathy. Joint Bone Spine. 2011;78:41–4.
- Ruff RL, Weissmann J. Endocrine myopathies. Neurol Clin. 1988;6:575–92.
- van Staa TP, Leufkens HGM, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int. 2002;13:777–87.
- Jick SS, Lieberman ES, Rahman MU, Choi HK. Glucocorticoid use, other associated factors, and the risk of tuberculosis. Arthritis Rheum. 2006;55:19–26.
- PredniSONE. In: Lexi-Drug. Lexicomp Online. Waltham, MA: UpToDate, Inc. https://online.lexi.com. Accessed February 8, 2022.